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OBJECTIVE—In diabetes, it remains unclear whether the coronary artery calcium (CAC)
score provides additional information about total mortality risk beyond traditional risk factors.
RESEARCH DESIGN AND METHODS—A total of 1,051 participants, aged 34–86
years, in the Diabetes Heart Study (DHS) were followed for 7.4 years. Subjects were separated
into ﬁve groups using baseline computed tomography scans and CAC scores (0–9, 10–99, 100–
299, 300–999, and $1,000). Logistic regression was performed adjusting for age, sex, race,
smoking, and LDL cholesterol to examine the association between CAC and all-cause mortal-
ity. Areas under the curve with and without CAC were compared. Natural splines using con-
tinuous measures of CAC were ﬁtted to estimate the relationship between observed CAC and
mortality risk.
RESULTS—A total of 17% (178 of 1,051) of participants died during the follow-up. In
multivariate analysis, the odds ratios (95% CIs) for all-cause mortality, using CAC 0–9a st h e
reference group, were CAC 10–99: 1.40 (0.57–3.74); CAC 100–299: 2.87 (1.17–7.77); CAC
300–999: 3.04 (1.32–7.90); and CAC $1,000: 6.71 (3.09–16.87). The area under the curve
without CAC was 0.68 (95% CI 0.66–0.70), and the area under the curve with CAC was 0.72
(0.70–0.74) (P = 0.0001). Using splines, the estimated risk (95% CI) of mortality for a CAC of
0 was 6.7% (4.6–9.7), and the risk increased nearly linearly, plateauing at CAC $1,000 (20.0%
[15.7–25.2]).
CONCLUSIONS—In diabetes, CAC was shown to be an independent predictor of mortality.
Participants with CAC (0–9) were at lower risk (0.9% annual mortality). The risk of mortality
increasedwith increasinglevelsofCAC,plateauingatapproximatelyCAC$1,000(2.7%annual
mortality).MoreresearchiswarrantedtodeterminethepotentialutilityofCACscansindiabetes.
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D
iabetes is a coronary heart disease
riskequivalent.Theassociatedhigh
overall mortality is largely attribut-
able to increased cardiovascular deaths
(1–3). Most of the morbidity and mortal-
ity in this high-risk condition are driven
by accelerated atherosclerosis (4), charac-
terizedbyincreasedamountsofconnective
tissue, glycoproteins, and calciﬁed plaque
in the blood vessels (5,6). Imaging by
computed tomography (CT) reveals that
individuals afﬂicted with diabetes have
extensive calciﬁcation of their vascular
beds (7–9).
Several studies have shown that sub-
clinical atherosclerosis, as measured by
coronary artery calcium (CAC), predicts
future cardiovascular disease (CVD)
events and death, independent of con-
ventional risk factors (10–12), in the gen-
eral population. Whether higher CAC
scores are associated with adverse clinical
outcomes, in particular all-cause mortal-
ity, in diabetes has not been studied
extensively. Because individuals with di-
abetes represent a group at high risk for
cardiovascular events and death, risk
stratiﬁcation may be particularly useful
in this population. This study examines
the risk of death in participants with di-
abetes across higher levels of CAC scores.
RESEARCH DESIGN AND
METHODS—The Diabetes Heart Study
(DHS) is a family study in which siblings
concordant for type 2 diabetes, as well as
unaffected family members, were recruited
frominternalmedicineandendocrinology
clinics in western North Carolina. The
DHS design has been described in detail
previously (5). To summarize, entry crite-
ria required index case subjects to be di-
agnosed with type 2 diabetes after the age
of 34 years and no historical evidence of
diabetic ketoacidosis. At least one type 2
diabetic sibling was recruited for each
index case subject enrolled. Additional
nondiabeticanddiabeticfamilymembers
also were enrolled, when possible. The
study was approved by the institutional
review board at the Wake Forest Univer-
sity School of Medicine, and all subjects
gave informed consent for all study pro-
tocols.
Laboratory measurements
The participant examinations were con-
ducted in the general clinical research
center of the Wake Forest University
Baptist Medical Center and included in-
terviews for medical history and health
behaviors and anthropometric measure-
ments. Participants were questioned
about smoking history. Measurements of
weight and height to the nearest 0.1 kg
and 0.5 cm, respectively, were obtained
during the visits, and resting blood pres-
sure was recorded. Hypertension was
deﬁned as the current use of any antihy-
pertensive medications or a resting systolic
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ORIGINAL ARTICLEblood pressure .140 mmHg or resting
diastolic blood pressure .90 mmHg.
Fasting laboratory assays for total choles-
terol, HDL cholesterol, triglycerides, glu-
cose, and hemoglobin A1c were obtained.
LDL cholesterol was calculated with the
Friedewald equation (13). Diabetes was
deﬁned by self-reported history of adult-
onset of diabetes, fasting glucose $126
mg/dL, or use of insulin or oral glucose-
lowering medications. The National
Cholesterol Education Program Adult
Treatment Panel (14) deﬁnition was used
to classify participants having metabolic
syndrome in the DHS cohort. Three of
ﬁve of the following components are re-
quired for diagnosis: 1) waist circumfer-
ence $102 cm for men and $88 cm for
women; 2) $130 mmHg systolic or $85
mmHg diastolic blood pressure or self-
reported use of medications for hyperten-
sion; 3) fasting blood glucose $100 mg/dL
or treatment for impaired fasting glu-
cose; 4) triglycerides $150 mg/dL or spe-
ciﬁc treatment; and 5)H D Lc h o l e s t e r o l
#40 mg/dL in men and #50 mg/dL in
women.
CAC
CAC was measured using fast-gated heli-
cal CT. All scans were performed on two
single-slice subsecond helical CT scan-
ners equipped for retrospective cardiac
gating and capable of 500-ms temporal
resolution (HiSpeed LX with the Smart
Score Cardiac Scan Package; General
Electric Medical Systems, Milwaukee,
WI). Participants were placed in the
supine position on the CT couch over
a quality-control calibration phantom
(Image Analysis, Columbia, KY). After
obtaining a scout image of the chest, a
helical volume of the entire heart during
suspended respiration at end inspiration
was obtained with the following parame-
ters: 3-mm slice thickness; 26-cm display
ﬁeld of view; retrospective cardiac gating,
120 kv, 240 mA; and CT scan pitch
adjusted to heart rate, as described pre-
viously (15). To further improve the pre-
cision of the calcium score, a replicated
scan was performed immediately after
the initial scan so that the average of the
two scores could be calculated. The re-
producibility of the calcium score was
high (r = 0.98, Spearman correlation co-
efﬁcient) between the ﬁrst and second
CAC scores. The amount of coronary
calcium was scored using a modiﬁed
Agatston method with the traditional
130-Henry U threshold and a minimal le-
siondeﬁnitionof0.52mm
2.Inapreviously
published work (15), this method has
very high correlation with the electron-
beam CT–derived measure of coronary
calcium (r =0 . 9 8 )a n dh i g ha g r e e m e n t
when categorizing individuals based on
their coronary calcium score.
All-cause mortality
The primary outcome, all-cause mortality
from any cause both cardiovascular and
noncardiovascular, was recorded for an
average of 7.4 years (range 4–12) after
CAC screening. At intervals of 9–12
months, an interviewer contacted each
participant or a family member by tele-
phone to inquire about well being and
death. For participants who had died, in-
terviews were conducted with the next-
of-kin, and copies of death certiﬁcates
were obtained. In addition, a search by
social security number in the national
death index also was performed to deter-
mine the status of subjects lost to follow-
up. Cardiovascular death was deﬁned as
death as a result of myocardial infarction,
congestive heart failure, cardiac arrhyth-
mia, sudden cardiac death, peripheral
vascular disease, and stroke. Noncardio-
vascular death was deﬁned as death due
to cancer, infection, end-stage renal dis-
ease, accident, Alzheimer’s dementia, and
others, such as chronic obstructive pul-
monary disease, pulmonary ﬁbrosis, and
liver failure.
Statistical analysis
Weusedx
2testsfordiscretevariablesand
one-way ANOVA for continuous varia-
bles to test fordifferencesindemographic
and risk factors between surviving and
deceased participants. The coronary cal-
cium score was examined both as a strati-
ﬁed variable and as a continuous variable.
Subjects were separated into ﬁve groups
on the basis of CAC scores derived from
baseline CT scans (CAC scores 0–9, 10–
99, 100–299, 300–999, and $1,000).
Logistic regression was used to esti-
mate odds ratios (ORs) for all-cause mor-
tality or death from any cause according
to the coronary calcium score. We con-
structed receiver-operating characteristic
(ROC) curves and compared the areas
under the ROC curves with and without
CAC in the model. Spline regression was
used in which calcium score was treated
as a continuous variable to estimate the
relationship between observed CAC and
the risk of mortality. Natural splines were
used to try to detect any nonlinear re-
lationship between CAC and risk for
all-cause mortality. The need for spline
ﬁtting (i.e., deviation from linearity) was
tested by the signiﬁcance of the spline
term in the logistic model using two
knots. Three knots were used if the ad-
dition of another spline term signiﬁcantly
improved the ﬁt of the model. Annual
mortality rates were calculated by divid-
ing the predicted mortality by total follow-
up time (in years). Additional analyses
were performed to test for an interaction
between CAC and all-cause mortality by
race and sex.
In a separate analysis that used coro-
nary calcium score as a continuous vari-
able, the base 2 logarithm of the sum of
the coronary calcium score plus 1 (log2
[CAC + 1]) was used. The choice of base
2 for the logarithm allowed us to examine
how a doubling of the calcium score af-
fects all-cause mortality, because each
unit difference in the log-transformed
calcium score represents a doubling of
the score. The addition of one to the cal-
cium score before logarithmic transfor-
mation allowed us to include in the
analysis participants with a calcium score
of zero. Additional multivariable analyses
with ordinal coronary calcium categories
topredictall-causemortalityalsowereper-
formed.
All models were adjusted for age, sex,
race, smoking, and LDL cholesterol. In
additional analyses, adjustment for dura-
tion of diabetes, hemoglobin A1c, systolic
blood pressure, and antihypertensive
medications also was undertaken. All sta-
tistical analyses were performed using
JMP version 8 (SAS Institute, Cary, NC).
RESULTS
Participant characteristics
Among 1,443 participants in the DHS
cohort, we excluded 224 nondiabetic
subjects and 168 subjects with missing
data (n = 61 for calcium score, n = 100 for
LDL cholesterol, and n = 7 for smoking).
The baseline characteristics of 1,051 par-
ticipants are shown in Table 1. The mean
age of participants was 61 years, .50%
of participants were female, and 17% of
participants were black. A total of 85% of
the participants had a CAC score .10.
Risk factors were equally distributed in
the two categories of mortality and no
mortality, with a slightly higher number
ofsmokersinthemortalitygroup.Signif-
icant differences were found between the
two categories, with higher mean CAC
scores and higher prevalence of CAC
scores $1,000 in the mortality group
(Table 1).
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During7.4yearsoffollow-up,178deaths
were identiﬁed. All-cause mortality in-
cludes both cardiovascular and noncar-
diovascular deaths. One hundred ﬁfty-
one individuals had a documented cause
of death, of which 82 participants died of
cardiovascular causes. There is an in-
creased incidence of all-cause mortality
with higher categories of CAC, with a P
trend of 0.0001 (Supplementary Fig. 1).
In a univariate analysis, the ORs (95%
CIs;Pvalues)forall-causemortalityusing
CAC scores 0–9 as a reference group were
CAC 10–99: 1.53 (0.64–4.08; 0.35); CAC
100–299: 3.13 (1.30–8.33; 0.01); CAC
300–999: 3.67 (1.64–9.34; 0.001); and
CAC $1,000: 8.26 (4.01–20.00; 0.0001).
When the models were further adjusted
for age, sex, race, smoking, and LDL cho-
lesterol,similarresultswereobserved(CAC
10–99: 1.40 [0.57–3.74; 0.47]; CAC 100–
299: 2.87 [1.17–7.77; 0.02]; CAC 300–
999: 3.04 [1.32–7.90; 0.008]; and CAC
$1,000: 6.71 [3.09–16.87; 0.0001])
(Fig. 1). In additional analyses, after fur-
ther adjusting for duration of diabetes,
hemoglobin A1c, systolic blood pressure,
and antihypertensive medications, the re-
sults were qualitatively similar (data not
shown).
The area under the ROC curve for the
predictionofall-causemortalitywas0.68,
using age, sex, race, smoking, and LDL
cholesterolaspredictors,andincreasedto
0.72 (P = 0.0001) with the addition of
CAC in the model.
When CAC was used as a continuous
measure using natural splines, the esti-
mated risk (95% CI) of mortality for
CAC = 0 was 6.7% (4.6–9.7) over 7.4
years, with an estimated annual mortality
of 0.9%. The estimated risk of mortality
for CAC $1,000 was 20.0% (15.7–25.2)
over 7.4 years (Fig. 2). In addition, the
risk of mortality increased nearly linearly
up to the CAC level of $1,000, where it
appeared to plateau and where additional
increments of calcium may not be infor-
mative (Fig. 2).
In a separate analysis, there was no
signiﬁcant interaction between CAC 3
race (P = 0.9) and CAC 3 sex (P =0 . 7 )
in the prediction of all-cause mortality. In
addition,in aseparate sensitivity analysis,
when using CAC as a continuous variable
in a full model, CAC was a signiﬁcant
predictor of mortality (P = 0.0001).
Supplementary Data Table 2 also shows
the increase in the risk of all-cause mor-
tality associated with a doubling of the
coronary calcium score (a 1-unit increase
in log2 [CAC + 1]). After adjustment for
potential confounders, a doubling of the
calcium score resulted in a 24% increase
in the risk of all-cause mortality. In an-
other multivariable analysis, the odds for
death increased by 65% in patients with
diabetes for every increase in CAC group-
ing from 10 to 99 to 100 to 299, 300 to
999, and .1,000 (P = 0.0001) (Supple-
mentary Table 1).
CONCLUSIONS—We examined the
predictive value of CAC for all-cause
mortality in a biracial population with
diabetes. In this cohort, we showed that
the presence of any coronary artery calci-
ﬁcation predicts risk for all-cause mortal-
ity compared with patients with diabetes
with no or minimal(CAC = 0–9)calcium.
In addition, the absence of CAC in-
dicated a low risk of mortality in this
high-risk population. CAC is an indepen-
dent predictor of mortality even in diabe-
tes,andtheuseofatherosclerosisimaging
may help improve risk assessment in this
high-risk condition.
The ﬁndings from this analysis cor-
roborate and extend previous observa-
tions. In a multiethnic population free of
CVD at baseline, the adjusted risk for
coronary events was increased by a factor
of 6.84 (95% CI 2.93–15.99) among par-
ticipants with CAC $300 compared with
participants with no CAC (10). Raggi
et al. (11) analyzed a cohort of 10,377
asymptomatic individuals with 903 pa-
tients with diabetes referred for CAC
imaging. The investigators found an in-
creased risk of all-cause mortality in pa-
tients with diabetes with higher CAC
scores with an OR (95% CI) of 5.76
(4.61–10.39) in CAC $1,000 compared
with CAC 0–10, which are similar to our
ﬁndings and a comparable mortality be-
tween patients with diabetes with no cal-
cium and nondiabetic subjects. We
compared the characteristics of patients
with diabetes with CAC 0–9v e r s u sC A C
$10 to ascertain the cause of this in-
creased risk of mortality (Table 2) and
found that patients with diabetes with
higher coronary scores had longer dura-
tion of disease, were older, were more
likely to be male, and were hypertensive
with higher mean systolic blood pres-
sure. However, even after adjustment
for diabetes duration, hemoglobin A1c,
systolic blood pressure, and antihyper-
tensive medications, the results were
qualitatively similar, highlighting the
signiﬁcance of CAC as an independent
risk predictor.
Table 1—Baseline demographic characteristics and risk factors stratiﬁed by all-cause
mortality in the DHS cohort
Variable All participants No death Death P
Age (years) 61.7 6 9.1 60.6 6 8.9 65.9 6 9.5 0.0001
Male sex (%) 480 (46) 383 (44) 97 (54) 0.01
Whites (%) 876 (83) 732 (84) 144 (81) 0.33
Blacks (%) 175 (17) 141 (16) 34 (19)
Current smokers (%) 174 (17) 134 (15) 40 (22) 0.02
Metabolic syndrome (%) 924 (88) 772 (88) 152 (85) 0.27
Hypertension (%) 930 (88) 769 (88) 161 (90) 0.36
Systolic blood pressure
(mmHg) 140.0 (18.9) 140.0 (18.1) 140.4 (22.3) 0.79
Fasting glucose (mg/dL) 147.2 (58.0) 146.2 (54.4) 152.1 (73.2) 0.22
Waist circumference (cm) 107.3 (16.9) 107.6 (16.8) 105.7 (17.4) 0.18
HDL cholesterol (mg/dL) 44.1 (12.6) 44.1 (12.2) 43.8 (14.5) 0.76
LDL cholesterol (mg/dL) 104.5 (33.2) 104.0 (33.4) 106.7 (32.3) 0.33
Triglycerides (mg/dL) 170.0 (83.3) 169.3 (83.2) 173.2 (84.1) 0.57
Average CAC score 1,706.1 (3,248.8) 1,405.1 (3,059.3) 3,182.5 (3,723.7) 0.0001
Prevalence of CAC
CAC ,10 143 (14) 136 (16) 7 (4) 0.0001
CAC 10–99 223 (21) 207 (24) 16 (9) 0.0001
CAC 100–299 125 (12) 108 (12) 17 (10) 0.31
CAC 300–999 186 (18) 157 (18) 29 (16) 0.67
CAC $1,000 371 (35) 262 (30) 109 (61) 0.0001
Data are n (%), or continuous measures are means 6 SD. P values were obtained by one-way ANOVA and
x
2 test. Subjects were divided into ﬁve groupsbased on the CAC score derived from baseline CT scans(CAC
0–9, 10–99, 100–299, 300–999, and $1,000).
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Agarwal and AssociatesA number of researchers, such as Qu
et al. (16), who studied 249 patients with
diabetes did not report any statistically
signiﬁcant increase in adverse cardiovas-
cular end points with increasing CAC
scores. This divergence is probably a re-
ﬂection of a smaller diabetic cohort com-
pared with the DHS cohort and also the
fact that the speciﬁc end points that were
examined were cardiovascular end points
and not all-cause mortality.
Diabetes is synonymous with CVD
(3), as subsequent cardiovascular mor-
bidity and mortality is similar to that of
individuals with known coronary heart
disease (1). This clinical observation
also is reﬂected by the presence of exten-
sive calciﬁcation in asymptomatic pa-
tients with diabetes, which is similar to
nondiabetic subjects with known coro-
nary heart disease on atherosclerosis im-
aging (9,17). However, among patients
with diabetes, a subset of individuals
without evidence of atherosclerosis
has a lower short to intermediate risk
for death, and here coronary imaging
may serve as a worthwhile tool for risk
stratiﬁcation.
The mechanism for advanced athero-
sclerosis in patients with diabetes is
almost certainly multifactorial. Hypergly-
cemia and glucosylated proteins lead to
activation of genes and enzymes involved
in calciﬁcation, atherogenesis and throm-
bosis (18,19), and medial artery calciﬁca-
tion, which substantially increases the
risk for coronary events (20).
There is an increasing prevalence of
obesity, metabolic syndrome, and diabe-
tes globally (21). Thus, timely diagnosis
of atherosclerosis in this high-risk group
isimperativetopreventfuturemicro-and
macrovascular complications. This risk-
stratiﬁcation strategy using CAC may
lead to better, novel, and aggressive indi-
vidualized therapy in this population,
perhaps resulting in decreased mortality,
which is not currently observed com-
pared with the general population (22).
Whether aggressive therapy needs to be
directed at those with or without ad-
vancedcalciﬁcationremainscontroversial
inlightoftherecentActiontoControlCar-
diovascular Risk in Diabetes (ACCORD)
trial, where intensive lowering of risk fac-
tors in patients with diabetes led to harm
rather than beneﬁt (23). Our results also
suggest that atherosclerosis is an indepen-
dent predictor of mortality in diabetes
independent of diabetes duration and dia-
betes control and conventional cardiovas-
cular risk factors.
The strength of this study is the in-
clusion of a large high-risk population of
only patients with diabetes with meta-
bolic syndrome with meticulous stan-
dardized measures of CAC and data
collection leading to generalizability in
thediabetic population. However, several
limitations need to be acknowledged. We
excludedinsulin-dependentpatientswith
diabetes from the analysis, but previous
studies show that both forms of disease
have increased coronary calciﬁcation
compared with nondiabetic subjects
(7,8). Thus, the results of the current
analysis may be applicable in insulin-
dependent patients with diabetes as
well. Selection of participants from a sin-
gle center may limit the generalizability
of results. Finally, the choice of all-cause
mortality rather than cardiovascular end
points may result in different outcomes.
However, the majority of fatal events in
patients with diabetes are cardiovascular
in nature, and it is now preferred as an
outcome in cardiovascular research (24).
In addition, in patients with diabetes, the
risks for CVD-only mortality and all-
cause mortality are similar (25).
Figure1—SubjectswereseparatedintoﬁvegroupsbasedonCACscorederivedfrombaselineCT
scans, CAC (0-9, 10-99, 100-299, 300-999, and $1,000). CAC ORs for all-cause mortality for
higherCACscoresincomparisontoCACscore,10.Modelsadjustedforage,sex,race,smoking,
and LDL cholesterol. ORs for all-cause mortality with higher CAC scores in the DHS cohort
compared with CAC scores ,10 in a full model.
Figure 2—Spline regression estimating probability of all-cause mortality and continuous cor-
onary calcium score: the DHS.
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Coronary calcium score and all-cause mortalityIn conclusion, coronary artery calci-
ﬁcation can serve as a tool for risk strat-
iﬁcation in a high-risk population of
patients with diabetes. In addition, pa-
tients with diabetes free of coronary cal-
ciﬁcation remain at a lower risk for
cardiovascular deaths. Whether imple-
mentation of aggressive medical manage-
ment in patients with diabetes with
advanced calciﬁcation leads to decreased
mortality remains to be determined. Fur-
thermore, whether aggressive manage-
ment of patients with diabetes with
absent coronary calciﬁcation leads to
further risk reduction also remains to be
seen.
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